15 completed, 2 recruiting, 1 active not recruiting, 1 enrolling by invitation. 8 Phase 1, 7 Phase 3, 3 Phase 2, 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 6, Recruiting 1, Withdrawn 1 |
| Phase 3 | 7 | Completed 7 |
| Phase 2 | 3 | Completed 3 |
| Phase 4 | 3 | Active not recruiting 1, Enrolling by invitation 1, Recruiting 1 |
Follow bexagliflozin: new trials by email Literature Review of bexagliflozin trials Research Report on bexagliflozin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG) Brenzavvy (bexagliflozin), 20 mg Oral Tablet, Placebo - Angina Patients With Non-obstructive Coronary Artery Disease, Coronary Microvascular Disease | Phase 1 | Recruiting | University of Virginia | 150 | 2025-07-15 | 2026-09-09 |
| Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists SGLT-2 inhibitor, GLP1-RA - Type 2 Diabetes (T2DM) | Phase 4 | Active not recruiting | MaryAnn Banerji | 60 | 2024-12-21 | 2026-01-08 |
| Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study Bexagliflozin 20 mg, Placebo - Sleep Apnea | Phase 4 | Recruiting | Yale University | 164 | 2024-03-27 | 2026-08-27 |
| Absolute Bioavailability Study With Bexagliflozin Bexagliflozin - Type 2 Diabetes Mellitus | Phase 1 | Withdrawn | Theracos | 2018-08-01 | 2019-09-30 | |
| Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment Bexagliflozin - Type2 Diabetes Mellitus | Phase 1 | Completed | Theracos | 16 | 2018-07-26 | 2021-06-03 |
| Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects Bexagliflozin tablets, 20 mg, Bexagliflozin tablets, placebo - Type2 Diabetes Mellitus | Phase 3 | Completed | Theracos | 351 | 2017-11-28 | 2021-07-07 |
| An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension Bexagliflozin, Placebo - Essential Hypertension | Phase 2 / Phase 3 | Completed | Theracos | 673 | 2017-10-18 | 2021-09-21 |
| Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects Bexagliflozin, Sitagliptin, Placebo for sitagliptin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Theracos | 386 | 2017-10-12 | 2021-06-22 |
| Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects Bexagliflozin, Probenecid, Rifampin - Type 2 Diabetes Mellitus | Phase 1 | Completed | Theracos | 48 | 2017-09-27 | 2021-07-01 |
| Bexagliflozin Drug/Drug Interaction Study With Digoxin Bexagliflozin, Digoxin - Type2 Diabetes Mellitus | Phase 1 | Completed | Theracos | 20 | 2017-07-24 | 2021-07-23 |
| Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection Bexagliflozin, Exenatide Injection - Type2 Diabetes Mellitus | Phase 1 | Completed | Theracos | 20 | 2017-05-24 | 2021-05-28 |
| Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin Bexagliflozin, Metformin, Glimepiride - Type2 Diabetes Mellitus | Phase 1 | Completed | Theracos | 54 | 2016-11-01 | 2021-07-22 |
| Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment Bexagliflozin, Placebo - Type 2 Diabetes Mellitus | Phase 3 | Completed | Theracos | 312 | 2016-09-23 | 2021-06-30 |
| Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects Bexagliflozin, Placebo for Bexagliflozin, Glimepiride - Type 2 Diabetes Mellitus | Phase 3 | Completed | Theracos | 426 | 2016-08-15 | 2021-05-27 |
| Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects Bexagliflozin - Type 2 Diabetes Mellitus | Phase 1 | Completed | Theracos | 25 | 2016-06-20 | 2021-06-10 |
| Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes Bexagliflozin, Placebo - Type 2 Diabetes Mellitus | Phase 3 | Completed | Theracos | 210 | 2016-03-01 | 2021-06-28 |
| Bexagliflozin Efficacy and Safety Trial Bexagliflozin, Placebo - Type 2 Diabetes Mellitus | Phase 3 | Completed | Theracos | 1700 | 2015-10-01 | 2021-07-14 |
| A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus Bexagliflozin tablets, Bexagliflozin tablets, placebo - Diabetes Mellitus, Type 2 | Phase 2 | Completed | Theracos | 292 | 2015-05-12 | 2021-06-29 |
| Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus EGT0001442, Placebo - Diabetes Mellitus | Phase 2 | Completed | Theracos | 288 | 2011-12-01 | 2021-07-01 |
Diabetes Mellitus, Type 2 (11) · Albuminuria (1) · Angina Pectoris (1) · Diabetes Mellitus (1) · Essential Hypertension (1) · Hyperkalemia (1) · Microvascular Angina (1) · Renal Insufficiency, Chronic (1) · Sleep Apnea Syndromes (1)
Theracos (16) · Baylor Research Institute (1) · MaryAnn Banerji (1) · University of Virginia (1) · Yale University (1)
United States (20) · Japan (4) · Poland (3) · Spain (3) · Canada (2) · Czechia (2) · Denmark (1) · France (1) · Germany (1) · Hungary (1) · Mexico (1) · Netherlands (1) · Russia (1) · South Korea (1) · Taiwan (1)
Mason Freeman, M.D. (5) · J. Paul Lock, MD (4) · Andrew Allegretti, M.D. (2) · Henry K Yaggi, M.D. (1) · Ian J Neeland, M.D. (1) · J Paul Lock, M.D. (1) · J. P. Lock, M.D. (1) · Mary Ann Banerji, MD (1) · Mason W Freeman, M.D. (1) · Patricia Rodriguez-Lozano, MD (1) · Robert Williams, M.D. (1)